A three-arm, randomized, open-label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenupausal women with estrogen receptor postive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole.
2022-06-29
عنوان الدراسة
A three-arm, randomized, open-label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenupausal women with estrogen receptor postive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole.
داعم الدراسة
Novartis
دواء الدراسة
Everolimus + Exemestane VS. Everolimus VS. Capecitabine
رقم بروتوكول الدراسة
CRAD001Y2201
حالة الدراسة
Rejected
موقع الدراسة
KFSH & RC-R
مرحلة الدراسة
2
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。